STOCK TITAN

[Form 4] GoDaddy Inc Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

The Form 4 filed on 07/03/2025 reports routine equity-compensation activity by Forte Biosciences (FBRX) CEO, Chair and Director Paul A. Wagner. On 07/01/2025 he converted 1,250 restricted stock units into an equal number of common shares (code M) at a $0 exercise price. To cover statutory taxes, 98 shares were automatically surrendered (code F) at $12.44 each. Following the transactions, Wagner now owns 80,940 FBRX shares directly and retains 7,500 unvested RSUs.

No open-market buying or selling occurred, no cash changed hands, and the share count involved is immaterial relative to Forte’s public float, so market impact should be limited. Nevertheless, the filing incrementally increases insider ownership and signals that vesting under the 2021 Equity Incentive Plan continues as scheduled.

Il modulo Form 4 presentato il 07/03/2025 riporta un'attività di routine relativa alla compensazione azionaria da parte di Paul A. Wagner, CEO, Presidente e Direttore di Forte Biosciences (FBRX). Il 01/07/2025 ha convertito 1.250 unità azionarie vincolate in un numero equivalente di azioni ordinarie (codice M) a un prezzo di esercizio di $0. Per coprire le tasse statutarie, 98 azioni sono state automaticamente cedute (codice F) al prezzo di $12,44 ciascuna. Dopo queste operazioni, Wagner possiede direttamente 80.940 azioni FBRX e detiene ancora 7.500 RSU non maturate.

Non si sono verificati acquisti o vendite sul mercato aperto, non sono stati scambiati contanti e il numero di azioni coinvolte è irrilevante rispetto al flottante pubblico di Forte, quindi l'impatto sul mercato dovrebbe essere limitato. Tuttavia, la comunicazione aumenta leggermente la proprietà interna e indica che il vesting previsto dal Piano di Incentivi Azionari 2021 procede come programmato.

El Formulario 4 presentado el 07/03/2025 informa una actividad rutinaria de compensación en acciones por parte de Paul A. Wagner, CEO, presidente y director de Forte Biosciences (FBRX). El 01/07/2025 convirtió 1.250 unidades restringidas en un número igual de acciones comunes (código M) con un precio de ejercicio de $0. Para cubrir impuestos legales, 98 acciones fueron automáticamente entregadas (código F) a $12,44 cada una. Tras estas transacciones, Wagner posee directamente 80.940 acciones de FBRX y mantiene 7.500 RSU no adquiridas.

No hubo compras ni ventas en el mercado abierto, no se intercambió dinero en efectivo y la cantidad de acciones involucradas es insignificante en relación con el flotante público de Forte, por lo que el impacto en el mercado debería ser limitado. Sin embargo, la presentación incrementa ligeramente la propiedad interna y señala que la adquisición bajo el Plan de Incentivos de Capital 2021 continúa según lo previsto.

2025년 7월 3일 제출된 Form 4는 Forte Biosciences(FBRX)의 CEO, 회장 및 이사인 Paul A. Wagner의 정기적인 주식 보상 활동을 보고합니다. 2025년 7월 1일에 그는 1,250개의 제한 주식 단위를 동일한 수의 보통주(코드 M)로 전환했으며, 행사 가격은 $0였습니다. 법정 세금을 충당하기 위해 98주의 주식이 자동으로 반납(코드 F)되었으며, 주당 $12.44에 처리되었습니다. 이 거래 후 Wagner는 직접 80,940주의 FBRX 주식을 보유하고 있으며, 아직 권리가 확정되지 않은 RSU 7,500주를 보유하고 있습니다.

시장 내 공개 매매는 없었고 현금 거래도 없었으며, 관련 주식 수는 Forte의 공공 유통 주식에 비해 미미하여 시장에 미치는 영향은 제한적일 것으로 보입니다. 그럼에도 불구하고 이번 신고는 내부자 소유 지분을 소폭 증가시키며 2021년 주식 인센티브 계획에 따른 권리 확정이 예정대로 진행 중임을 시사합니다.

Le formulaire 4 déposé le 03/07/2025 rapporte une activité courante de compensation en actions par Paul A. Wagner, PDG, président et directeur de Forte Biosciences (FBRX). Le 01/07/2025, il a converti 1 250 unités d'actions restreintes en un nombre égal d'actions ordinaires (code M) à un prix d'exercice de 0 $. Pour couvrir les impôts légaux, 98 actions ont été automatiquement remises (code F) au prix de 12,44 $ chacune. Après ces transactions, Wagner détient directement 80 940 actions FBRX et conserve 7 500 RSU non acquises.

Aucun achat ou vente sur le marché ouvert n'a eu lieu, aucun échange d'argent liquide n'a eu lieu, et le nombre d'actions impliquées est négligeable par rapport au flottant public de Forte, de sorte que l'impact sur le marché devrait être limité. Néanmoins, le dépôt augmente légèrement la propriété des initiés et indique que l'acquisition des droits dans le cadre du Plan d'incitation en actions 2021 se poursuit comme prévu.

Das am 03.07.2025 eingereichte Formular 4 berichtet über routinemäßige Aktienvergütungsaktivitäten von Paul A. Wagner, CEO, Vorsitzender und Direktor von Forte Biosciences (FBRX). Am 01.07.2025 wandelte er 1.250 Restricted Stock Units in die gleiche Anzahl von Stammaktien (Code M) zu einem Ausübungspreis von 0 $ um. Zur Deckung der gesetzlichen Steuern wurden automatisch 98 Aktien abgegeben (Code F) zu je 12,44 $. Nach den Transaktionen besitzt Wagner nun direkt 80.940 FBRX-Aktien und hält 7.500 unverfallbare RSUs.

Es gab keine Käufe oder Verkäufe am offenen Markt, es wurde kein Bargeld ausgetauscht, und die Anzahl der beteiligten Aktien ist im Verhältnis zum öffentlichen Streubesitz von Forte unerheblich, sodass die Marktauswirkungen begrenzt sein sollten. Dennoch erhöht die Meldung die Insider-Beteiligung leicht und signalisiert, dass die Vesting-Phase des Equity Incentive Plans 2021 planmäßig fortschreitet.

Positive
  • Incremental increase in insider ownership: CEO now directly holds 80,940 shares, marginally improving management–shareholder alignment.
Negative
  • None.

Insights

TL;DR: CEO exercised 1,250 RSUs, withheld 98 shares for taxes; ownership now 80,940 shares—neutral, routine vesting.

The transaction is a standard RSU conversion (code M) coupled with share withholding for taxes (code F). Dollar value is roughly $15k—far below any materiality threshold for Forte’s capitalization. Because there was no discretionary open-market purchase or sale, it neither signals bullishness nor concern. Insider ownership inches up, aligning incentives, but I judge the event non-impactful for valuation or liquidity.

TL;DR: Filing shows scheduled vesting under 2021 plan; governance hygiene intact, no red flags.

The Form 4 confirms compensation mechanics: quarterly vesting of RSUs with automatic tax withholding. Such transparency supports good governance practices. The CEO still holds 7,500 unvested RSUs, maintaining performance alignment. There is no indication of accelerated vesting, pledging, or unusual derivative use. I classify the disclosure as neutral for governance risk assessments.

Il modulo Form 4 presentato il 07/03/2025 riporta un'attività di routine relativa alla compensazione azionaria da parte di Paul A. Wagner, CEO, Presidente e Direttore di Forte Biosciences (FBRX). Il 01/07/2025 ha convertito 1.250 unità azionarie vincolate in un numero equivalente di azioni ordinarie (codice M) a un prezzo di esercizio di $0. Per coprire le tasse statutarie, 98 azioni sono state automaticamente cedute (codice F) al prezzo di $12,44 ciascuna. Dopo queste operazioni, Wagner possiede direttamente 80.940 azioni FBRX e detiene ancora 7.500 RSU non maturate.

Non si sono verificati acquisti o vendite sul mercato aperto, non sono stati scambiati contanti e il numero di azioni coinvolte è irrilevante rispetto al flottante pubblico di Forte, quindi l'impatto sul mercato dovrebbe essere limitato. Tuttavia, la comunicazione aumenta leggermente la proprietà interna e indica che il vesting previsto dal Piano di Incentivi Azionari 2021 procede come programmato.

El Formulario 4 presentado el 07/03/2025 informa una actividad rutinaria de compensación en acciones por parte de Paul A. Wagner, CEO, presidente y director de Forte Biosciences (FBRX). El 01/07/2025 convirtió 1.250 unidades restringidas en un número igual de acciones comunes (código M) con un precio de ejercicio de $0. Para cubrir impuestos legales, 98 acciones fueron automáticamente entregadas (código F) a $12,44 cada una. Tras estas transacciones, Wagner posee directamente 80.940 acciones de FBRX y mantiene 7.500 RSU no adquiridas.

No hubo compras ni ventas en el mercado abierto, no se intercambió dinero en efectivo y la cantidad de acciones involucradas es insignificante en relación con el flotante público de Forte, por lo que el impacto en el mercado debería ser limitado. Sin embargo, la presentación incrementa ligeramente la propiedad interna y señala que la adquisición bajo el Plan de Incentivos de Capital 2021 continúa según lo previsto.

2025년 7월 3일 제출된 Form 4는 Forte Biosciences(FBRX)의 CEO, 회장 및 이사인 Paul A. Wagner의 정기적인 주식 보상 활동을 보고합니다. 2025년 7월 1일에 그는 1,250개의 제한 주식 단위를 동일한 수의 보통주(코드 M)로 전환했으며, 행사 가격은 $0였습니다. 법정 세금을 충당하기 위해 98주의 주식이 자동으로 반납(코드 F)되었으며, 주당 $12.44에 처리되었습니다. 이 거래 후 Wagner는 직접 80,940주의 FBRX 주식을 보유하고 있으며, 아직 권리가 확정되지 않은 RSU 7,500주를 보유하고 있습니다.

시장 내 공개 매매는 없었고 현금 거래도 없었으며, 관련 주식 수는 Forte의 공공 유통 주식에 비해 미미하여 시장에 미치는 영향은 제한적일 것으로 보입니다. 그럼에도 불구하고 이번 신고는 내부자 소유 지분을 소폭 증가시키며 2021년 주식 인센티브 계획에 따른 권리 확정이 예정대로 진행 중임을 시사합니다.

Le formulaire 4 déposé le 03/07/2025 rapporte une activité courante de compensation en actions par Paul A. Wagner, PDG, président et directeur de Forte Biosciences (FBRX). Le 01/07/2025, il a converti 1 250 unités d'actions restreintes en un nombre égal d'actions ordinaires (code M) à un prix d'exercice de 0 $. Pour couvrir les impôts légaux, 98 actions ont été automatiquement remises (code F) au prix de 12,44 $ chacune. Après ces transactions, Wagner détient directement 80 940 actions FBRX et conserve 7 500 RSU non acquises.

Aucun achat ou vente sur le marché ouvert n'a eu lieu, aucun échange d'argent liquide n'a eu lieu, et le nombre d'actions impliquées est négligeable par rapport au flottant public de Forte, de sorte que l'impact sur le marché devrait être limité. Néanmoins, le dépôt augmente légèrement la propriété des initiés et indique que l'acquisition des droits dans le cadre du Plan d'incitation en actions 2021 se poursuit comme prévu.

Das am 03.07.2025 eingereichte Formular 4 berichtet über routinemäßige Aktienvergütungsaktivitäten von Paul A. Wagner, CEO, Vorsitzender und Direktor von Forte Biosciences (FBRX). Am 01.07.2025 wandelte er 1.250 Restricted Stock Units in die gleiche Anzahl von Stammaktien (Code M) zu einem Ausübungspreis von 0 $ um. Zur Deckung der gesetzlichen Steuern wurden automatisch 98 Aktien abgegeben (Code F) zu je 12,44 $. Nach den Transaktionen besitzt Wagner nun direkt 80.940 FBRX-Aktien und hält 7.500 unverfallbare RSUs.

Es gab keine Käufe oder Verkäufe am offenen Markt, es wurde kein Bargeld ausgetauscht, und die Anzahl der beteiligten Aktien ist im Verhältnis zum öffentlichen Streubesitz von Forte unerheblich, sodass die Marktauswirkungen begrenzt sein sollten. Dennoch erhöht die Meldung die Insider-Beteiligung leicht und signalisiert, dass die Vesting-Phase des Equity Incentive Plans 2021 planmäßig fortschreitet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sine Jared F.

(Last) (First) (Middle)
C/O GODADDY INC.
100 S. MILL AVE. SUITE 1600

(Street)
TEMPE AZ 85281

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GoDaddy Inc. [ GDDY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Strategy & Legal Officer
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 07/01/2025 S(1) 475 D $179.68 67,861 D
Class A Common Stock 07/02/2025 S 973(2) D $177.08 66,888 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The shares were sold pursuant to a 10b5-1 trading plan.
2. Represents shares of Class A Common Stock of the Issuer sold to satisfy the Reporting Person's tax withholding obligations, which were incurred in connection with the vesting of Restricted Stock Units. In accordance with company policy, shares are automatically sold to cover such obligations.
Remarks:
Jessica Craig, Attorney-in-Fact 07/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Forte Biosciences (FBRX) report in the latest Form 4?

CEO Paul A. Wagner converted 1,250 RSUs into common stock and withheld 98 shares for taxes.

How many Forte Biosciences shares does the CEO own after the transaction?

He directly owns 80,940 shares and holds 7,500 unvested RSUs.

What are transaction codes M and F on Form 4?

M is an option/RSU conversion; F is a share disposal to satisfy tax withholding.

Was there an open-market sale or purchase of FBRX shares?

No, the activity was limited to RSU vesting and tax withholding—no cash sale or purchase.

Does the filing indicate any change to Forte Biosciences’ financial outlook?

No. The event is routine compensation vesting and does not affect the company’s operations or outlook.
Godaddy Inc

NYSE:GDDY

GDDY Rankings

GDDY Latest News

GDDY Latest SEC Filings

GDDY Stock Data

25.25B
141.52M
0.73%
98.96%
1.89%
Software - Infrastructure
Services-computer Integrated Systems Design
Link
United States
TEMPE